Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 791

1.

Children and adolescents with epilepsy in rehabilitation centers: A French prospective transversal study.

Coste-Zeitoun D, Kuchenbuch M, Pennaroli D, Castaignède C, Napuri S, Satre C, Schaff JL, Sukno S, Hélias M, de Grissac-Moriez N, Delattolas G, Olive D, Bulteau C, Zeitoun G, Kaminska A.

Epilepsy Behav. 2020 Mar;104(Pt A):106898. doi: 10.1016/j.yebeh.2019.106898. Epub 2020 Jan 24.

PMID:
31986442
2.

[Next generation of anti-immune checkpoints antibodies].

Bonnefoy N, Olive D, Vanhove B.

Med Sci (Paris). 2019 Dec;35(12):966-974. doi: 10.1051/medsci/2019193. Epub 2020 Jan 6. French.

PMID:
31903901
3.

HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.

Malissen N, Macagno N, Granjeaud S, Granier C, Moutardier V, Gaudy-Marqueste C, Habel N, Mandavit M, Guillot B, Pasero C, Tartour E, Ballotti R, Grob JJ, Olive D.

Oncoimmunology. 2019 Sep 25;8(12):e1665976. doi: 10.1080/2162402X.2019.1665976. eCollection 2019.

4.

Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.

Amatore F, Gorvel L, Olive D.

Expert Opin Biol Ther. 2020 Feb;20(2):141-150. doi: 10.1080/14712598.2020.1693540. Epub 2019 Nov 28.

PMID:
31738626
5.

Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D.

Oncotarget. 2019 Sep 10;10(52):5493. doi: 10.18632/oncotarget.27198. eCollection 2019 Sep 10.

6.

Morcellation for Gynecologic Surgery.

Parker W, Pritts E, Olive D.

Clin Obstet Gynecol. 2019 Dec;62(4):727-732. doi: 10.1097/GRF.0000000000000485.

PMID:
31498239
7.

Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies.

Marrella A, Dondero A, Aiello M, Casu B, Olive D, Regis S, Bottino C, Pende D, Meazza R, Caluori G, Castriconi R, Scaglione S.

Front Immunol. 2019 Aug 9;10:1876. doi: 10.3389/fimmu.2019.01876. eCollection 2019.

8.

Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma.

Rochigneux P, Nault JC, Mallet F, Chretien AS, Barget N, Garcia AJ, Del Pozo L, Bourcier V, Blaise L, Grando-Lemaire V, N'Kontchou G, Nahon P, Seror O, Ziol M, Ganne-Carrié N, Olive D.

Oncoimmunology. 2019 May 25;8(8):1615818. doi: 10.1080/2162402X.2019.1615818. eCollection 2019.

9.

Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.

Karkeni E, Morin SO, Bou Tayeh B, Goubard A, Josselin E, Castellano R, Fauriat C, Guittard G, Olive D, Nunès JA.

Front Immunol. 2019 Jun 6;10:1307. doi: 10.3389/fimmu.2019.01307. eCollection 2019.

10.

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

Incorvaia L, Badalamenti G, Rinaldi G, Iovanna JL, Olive D, Swayden M, Terruso L, Vincenzi B, Fulfaro F, Bazan V, Russo A, Fanale D.

Ther Adv Med Oncol. 2019 May 13;11:1758835919848872. doi: 10.1177/1758835919848872. eCollection 2019.

11.

A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system.

Burlion A, Ramos RN, Kc P, Sendeyo K, Corneau A, Ménétrier-Caux C, Piaggio E, Olive D, Caux C, Marodon G.

Oncoimmunology. 2019 Apr 12;8(7):1596005. doi: 10.1080/2162402X.2019.1596005. eCollection 2019.

12.

Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function.

Degos C, Heinemann M, Barrou J, Boucherit N, Lambaudie E, Savina A, Gorvel L, Olive D.

Front Immunol. 2019 Apr 26;10:877. doi: 10.3389/fimmu.2019.00877. eCollection 2019.

13.

An X-ray Vision for Phosphoantigen Recognition.

Dustin ML, Scotet E, Olive D.

Immunity. 2019 Apr 16;50(4):1026-1028. doi: 10.1016/j.immuni.2019.03.015.

PMID:
30995494
14.

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.

Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien AS, Incorvaia L, Russo A, Olive D, Iovanna J.

Oncoimmunology. 2019 Feb 3;8(4):e1561120. doi: 10.1080/2162402X.2018.1561120. eCollection 2019.

15.

Two Modest Proposals: Thoughts from the Myoma/Leiomyosarcoma Controversies.

Olive DL.

J Minim Invasive Gynecol. 2019 Sep - Oct;26(6):993-994. doi: 10.1016/j.jmig.2019.03.010. Epub 2019 Mar 20. No abstract available.

PMID:
30904485
16.

PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua.

Vacca P, Pesce S, Greppi M, Fulcheri E, Munari E, Olive D, Mingari MC, Moretta A, Moretta L, Marcenaro E.

Mucosal Immunol. 2019 May;12(3):624-631. doi: 10.1038/s41385-019-0141-9. Epub 2019 Feb 12.

PMID:
30755717
17.

Fonctions de CD28, CTLA-4 et PD-1.

Olive D.

Bull Cancer. 2018 Dec;105 Suppl 1:S3-S15. doi: 10.1016/S0007-4551(18)30385-0. French.

PMID:
30595196
18.

PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.

Heskamp S, Wierstra PJ, Molkenboer-Kuenen JDM, Sandker GW, Thordardottir S, Cany J, Olive D, Bussink J, Boerman OC, Dolstra H, Aarntzen EHJG, Hobo WA.

Cancer Immunol Res. 2019 Jan;7(1):150-161. doi: 10.1158/2326-6066.CIR-18-0280. Epub 2018 Nov 20.

19.

T lymphocyte subsets in cancer immunity: Friends or foes.

Chraa D, Naim A, Olive D, Badou A.

J Leukoc Biol. 2019 Feb;105(2):243-255. doi: 10.1002/JLB.MR0318-097R. Epub 2018 Nov 2. Review.

PMID:
30387907
20.

CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas.

Le KS, Amé-Thomas P, Tarte K, Gondois-Rey F, Granjeaud S, Orlanducci F, Foucher ED, Broussais F, Bouabdallah R, Fest T, Leroux D, Yadavilli S, Mayes PA, Xerri L, Olive D.

Blood Adv. 2018 Aug 14;2(15):1889-1900. doi: 10.1182/bloodadvances.2018017244.

21.

New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity.

Blazquez JL, Benyamine A, Pasero C, Olive D.

Front Immunol. 2018 Jul 11;9:1601. doi: 10.3389/fimmu.2018.01601. eCollection 2018. Review.

22.

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.

Foucher ED, Ghigo C, Chouaib S, Galon J, Iovanna J, Olive D.

Front Immunol. 2018 May 14;9:1044. doi: 10.3389/fimmu.2018.01044. eCollection 2018. Review.

23.

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.

Le Roy A, Prébet T, Castellano R, Goubard A, Riccardi F, Fauriat C, Granjeaud S, Benyamine A, Castanier C, Orlanducci F, Ben Amara A, Pont F, Fournié JJ, Collette Y, Mege JL, Vey N, Olive D.

Front Immunol. 2018 May 4;9:977. doi: 10.3389/fimmu.2018.00977. eCollection 2018.

24.

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.

Faure M, Rochigneux P, Olive D, Taix S, Brenot-Rossi I, Gilabert M.

Front Immunol. 2018 Apr 19;9:797. doi: 10.3389/fimmu.2018.00797. eCollection 2018.

25.

Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation".

Parker WH, Berek JS, Pritts EA, Olive D, Chalas E, Clarke-Pearson D.

J Minim Invasive Gynecol. 2018 Sep - Oct;25(6):1113. doi: 10.1016/j.jmig.2018.04.008. Epub 2018 Apr 18. No abstract available.

PMID:
29679676
26.

The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells.

Janovec V, Aouar B, Font-Haro A, Hofman T, Trejbalova K, Weber J, Chaperot L, Plumas J, Olive D, Dubreuil P, Nunès JA, Stranska R, Hirsch I.

Front Immunol. 2018 Feb 26;9:364. doi: 10.3389/fimmu.2018.00364. eCollection 2018.

27.

Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.

Borie C, Mondal S, Arif T, Briand M, Lingua H, Dumur F, Gigmes D, Stocker P, Barbarat B, Robert V, Nicoletti C, Olive D, Maresca M, Nechab M.

Eur J Med Chem. 2018 Mar 25;148:306-313. doi: 10.1016/j.ejmech.2018.02.030. Epub 2018 Feb 12.

PMID:
29471119
28.

Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.

Amatore F, Gorvel L, Olive D.

Expert Opin Ther Targets. 2018 Apr;22(4):343-351. doi: 10.1080/14728222.2018.1444753. Epub 2018 Mar 1. Review.

PMID:
29468927
29.

BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).

Benyamine A, Loncle C, Foucher E, Blazquez JL, Castanier C, Chrétien AS, Modesti M, Secq V, Chouaib S, Gironella M, Vila-Navarro E, Montalto G, Dagorn JC, Dusetti N, Iovanna J, Olive D.

Oncoimmunology. 2017 Sep 21;7(1):e1372080. doi: 10.1080/2162402X.2017.1372080. eCollection 2017.

30.

Alternative facts and morcellation.

Olive DL.

Curr Opin Obstet Gynecol. 2018 Feb;30(1):60-64. doi: 10.1097/GCO.0000000000000436. Review.

PMID:
29227303
31.

NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.

Chretien AS, Devillier R, Fauriat C, Orlanducci F, Harbi S, Le Roy A, Rey J, Bouvier Borg G, Gautherot E, Hamel JF, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Blaise D, Olive D.

Oncoimmunology. 2017 Mar 24;6(12):e1307491. doi: 10.1080/2162402X.2017.1307491. eCollection 2017.

32.

Regarding "Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation".

Parker WH, Berek JS, Pritts EA, Olive D, Chalas E, Clarke-Pearson D.

J Minim Invasive Gynecol. 2018 Jan;25(1):187-188. doi: 10.1016/j.jmig.2017.07.027. Epub 2017 Aug 18. No abstract available.

PMID:
28826956
33.

NKG2C+ memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147.

Gondois-Rey F, Chéret A, Granjeaud S, Mallet F, Bidaut G, Lécuroux C, Ploquin M, Müller-Trutwin M, Rouzioux C, Avettand-Fenoël V, Moretta A, Pialoux G, Goujard C, Meyer L, Olive D.

Clin Transl Immunology. 2017 Jul 7;6(7):e150. doi: 10.1038/cti.2017.22. eCollection 2017 Jul.

34.

Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model.

Burlion A, Brunel S, Petit NY, Olive D, Marodon G.

Front Immunol. 2017 Jun 30;8:756. doi: 10.3389/fimmu.2017.00756. eCollection 2017.

35.

Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.

Chretien AS, Fauriat C, Orlanducci F, Galseran C, Rey J, Bouvier Borg G, Gautherot E, Granjeaud S, Hamel-Broza JF, Demerle C, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Gregori E, Luche H, Malissen M, Arnoulet C, Nunes JA, Vey N, Olive D.

Front Immunol. 2017 May 29;8:573. doi: 10.3389/fimmu.2017.00573. eCollection 2017.

36.

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.

Spodzieja M, Lach S, Iwaszkiewicz J, Cesson V, Kalejta K, Olive D, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowidło S.

PLoS One. 2017 Jun 8;12(6):e0179201. doi: 10.1371/journal.pone.0179201. eCollection 2017.

37.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D.

Oncotarget. 2017 Jul 25;8(30):49548-49563. doi: 10.18632/oncotarget.17747. Erratum in: Oncotarget. 2019 Sep 10;10(52):5493.

38.

Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.

Djaoud Z, Guethlein LA, Horowitz A, Azzi T, Nemat-Gorgani N, Olive D, Nadal D, Norman PJ, Münz C, Parham P.

J Exp Med. 2017 Jun 5;214(6):1827-1841. doi: 10.1084/jem.20161017. Epub 2017 May 3.

39.

The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human Vγ9Vδ2 T Cells.

Peigné CM, Léger A, Gesnel MC, Konczak F, Olive D, Bonneville M, Breathnach R, Scotet E.

J Immunol. 2017 Jun 1;198(11):4228-4234. doi: 10.4049/jimmunol.1601910. Epub 2017 May 1.

40.

NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27.

Dondero A, Casu B, Bellora F, Vacca A, De Luisi A, Frassanito MA, Cantoni C, Gaggero S, Olive D, Moretta A, Bottino C, Castriconi R.

Oncotarget. 2017 May 23;8(21):35088-35102. doi: 10.18632/oncotarget.17070.

41.

Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.

Xerri L, Huet S, Venstrom JM, Szafer-Glusman E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Laurent C, Gelas-Dore B, Bolen CR, Punnoose E, Bouabdallah R, Brice P, Morschhauser F, Cartron G, Olive D, Salles G; a LYSA study.

Hum Pathol. 2017 Jun;64:128-136. doi: 10.1016/j.humpath.2017.03.023. Epub 2017 Apr 13.

PMID:
28414090
42.

Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation.

Starick L, Riano F, Karunakaran MM, Kunzmann V, Li J, Kreiss M, Amslinger S, Scotet E, Olive D, De Libero G, Herrmann T.

Eur J Immunol. 2017 Jun;47(6):982-992. doi: 10.1002/eji.201646818. Epub 2017 Apr 27.

43.

Evolutionary and polymorphism analyses reveal the central role of BTN3A2 in the concerted evolution of the BTN3 gene family.

Afrache H, Pontarotti P, Abi-Rached L, Olive D.

Immunogenetics. 2017 Jun;69(6):379-390. doi: 10.1007/s00251-017-0980-z. Epub 2017 Apr 5.

PMID:
28382515
44.

A Mature NK Profile at the Time of HIV Primary Infection Is Associated with an Early Response to cART.

Gondois-Rey F, Chéret A, Mallet F, Bidaut G, Granjeaud S, Lécuroux C, Ploquin M, Müller-Trutwin M, Rouzioux C, Avettand-Fenoël V, De Maria A, Pialoux G, Goujard C, Meyer L, Olive D.

Front Immunol. 2017 Feb 10;8:54. doi: 10.3389/fimmu.2017.00054. eCollection 2017.

45.

Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells.

Rey J, Fauriat C, Kochbati E, Orlanducci F, Charbonnier A, D'Incan E, Andre P, Romagne F, Barbarat B, Vey N, Olive D.

Front Immunol. 2017 Feb 2;8:64. doi: 10.3389/fimmu.2017.00064. eCollection 2017.

46.

Abdominal vs Minimally Invasive Hysterectomy.

Pritts EA, Olive DL, Clarke-Pearson D.

JAMA. 2016 Dec 27;316(24):2677. doi: 10.1001/jama.2016.17819. No abstract available.

PMID:
28027360
47.

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.

M-Rabet M, Cabaud O, Josselin E, Finetti P, Castellano R, Farina A, Agavnian-Couquiaud E, Saviane G, Collette Y, Viens P, Gonçalves A, Ginestier C, Charafe-Jauffret E, Birnbaum D, Olive D, Bertucci F, Lopez M.

Ann Oncol. 2017 Apr 1;28(4):769-776. doi: 10.1093/annonc/mdw678.

48.

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.

Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, Pouyet L, Goubard A, Collette Y, Vey N, Scotet E, Castellano R, Olive D.

Oncoimmunology. 2016 Apr 25;5(10):e1146843. eCollection 2016.

49.

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.

Beldi-Ferchiou A, Lambert M, Dogniaux S, Vély F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbé C, Sène D, Hivroz C, Caillat-Zucman S.

Oncotarget. 2016 Nov 8;7(45):72961-72977. doi: 10.18632/oncotarget.12150.

50.

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D.

Oncoimmunology. 2016 May 19;5(7):e1186323. doi: 10.1080/2162402X.2016.1186323. eCollection 2016 Jul.

Supplemental Content

Support Center